Navigation Links
Data From LigoCyte's Clinical Studies of Norovirus VLP Vaccine Presented at 13th Annual Conference on Vaccine Research
Date:4/28/2010

BETHESDA, Md., April 28 /PRNewswire/ -- LigoCyte Pharmaceuticals, Inc., a private biopharmaceutical company focused on the development of innovative vaccine products, announced today that results from two Phase I studies of its norovirus virus-like particle (VLP) vaccine candidate were presented today at the 13th Annual Conference on Vaccine Research. Sponsored by the National Foundation of Infectious Diseases, the conference is being held in Bethesda, Maryland, from April 26-28, 2010.

Donald P. Beeman, Chief Executive Officer of LigoCyte, commented, "Each year, nearly 23 million Americans are infected with norovirus, the leading worldwide cause of infectious gastroenteritis, or inflammation of the stomach and intestines marked by acute vomiting and diarrhea. Epidemic outbreaks in hospitals, nursing homes and schools highlight this virus's significant burden, including serious and sometimes life-threatening complications.

"Given the urgency for prevention strategies, we are excited that Phase I data for LigoCyte's novel norovirus vaccine could be shared at NFID's Annual Conference on Vaccine Research."

Data presented during the conference were from two Phase I trials evaluating different dosage levels of the norovirus VLP vaccine candidate. The objective of the double-blind studies was to evaluate the vaccine's safety and immunogenicity in healthy volunteers, ages 18-49. Subjects were randomized to receive two doses of intranasal norovirus VLP vaccine (containing a Norwalk strain) or controls 21 days apart.  The clinical results showed the vaccine to be immunogenic and generally well tolerated in human subjects. Local nasal symptoms, including for example nasal stuffiness, were common and general
'/>"/>

SOURCE LigoCyte Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioMedix Receives Clinical Approval for TRAKnet Software
2. Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week
3. Suzie Williams, CP Joins Orthocare Innovations as Clinical Services Manager
4. Kristalose(R) Clinical Data to Be Presented at Digestive Disease Week(R) Meeting
5. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
6. AFFiRiS AG: Alzheimers Vaccine AD02 Already in Clinical Phase II
7. Gelesis Unveils Novel Non-Invasive Capsulated Device for Obesity and Presents Clinical Data; Appoints Former Pfizer R&D President to Board
8. PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention
9. Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications
10. Creating Healthcare Reform from the Inside Out Through Supply Chain Best Practices that Improve Financial and Clinical Performance is Focus of 2010 GHX Supply Chain Summit
11. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
(Date:1/23/2015)... Africa , Jan. 23, 2015   Leatt Corporation ... personal protective equipment for all forms of sports, including ... Leatt-Brace® neck brace, announced today that the UISP Lega ... now requires all riders to wear a neck brace ...
(Date:1/23/2015)... (NYSE: MNK ) announced today that its ... The open-ended authorization permits the company to repurchase up ... "Funding additional initiatives and seeking attractive business ... pursue a range of focused growth strategies," said ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... 8, 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Product Development of BioMarin, will present a company update at ... June 15, 2011 at 10:00 a.m. CT.   ... conference call via the investor section of the BioMarin website, ...
... About 20,000 children in the United States under the ... For many, the disease goes beyond painful red, dry ... equally life altering—with nearly 50 percent of children reporting ...  The XTRAC® Excimer Laser ( www.XTRACLaser.com ) offers new hope ...
Cached Medicine Technology:BioMarin to Present at the William Blair Growth Stock Conference 2XTRAC Laser Provides New Hope for Children with Psoriasis 2XTRAC Laser Provides New Hope for Children with Psoriasis 3
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 The Incredible ... Bodybuilder Ben Pakulski to increase lean muscle by up to ... has caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an ... that it is a step-by-step, scientific diet formula that allows ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and ... Merchandise Show to bestow a Juvent Sports Achievement award ... Arlene McKitrick. The award commemorated and congratulated McKitrick for ... She won her first amateur tournament in 1979 and ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post ... insurance . , Purchasing an accidental death and dismemberment ... This type of rider provides benefits if the insured dies ... a lesser form of life insurance. , AD&D is ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... is a famous dress online store for wedding dresses and ... collection of wedding dresses , and launches a site-wide women’s ... dress on your big day; the wedding gown is the ... to find the most suitable wedding dress. Now, we are ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... New evidence suggests screening for colorectal cancer, which is ... people, should start five to 10 years earlier for ... a University of Rochester Medical Center study said. , ... were diagnosed with colon cancer approximately seven years earlier ...
... ATLANTA, Feb. 13 Vendormate, Inc. announced ... America (CHCA) to make,Vendormate VISION(TM), its vendor ... children,s hospitals. Vendormate VISION(TM) is,used by leading ... better manage,the increasingly complex requirements of government-mandated ...
... at The Wistar Institute have collaborated on a major advance ... the deadliest cancers in humans. The culmination of 10 years ... new cancer therapies. , During much of its lifetime, ... in an inactive form, stored inside densely knotted structures in ...
... TRIANGLE PARK, N.C., Feb. 13 Quintiles,Transnational Corp. ... been certified by the College of American Pathologists ... supporting clinical trials in the first,quarter of 2007. ... been adding,services and analytical capabilities to a growing ...
... Corporation,(NYSE: SYK ) today announced that its Board ... $750 million of its common stock. Purchases may,be made ... privately negotiated,transactions or otherwise. The manner, timing and amount ... based on their evaluation of,market conditions, stock price and ...
... results further convinces Accipiter ... NEW YORK, Feb. 13 Accipiter Capital Management, the,owner, ... outstanding,shares of common stock of VistaCare, Inc. (Nasdaq: ... to VistaCare,s Board of Directors stating,that a review of ...
Cached Medicine News:Health News:Smokers might benefit from earlier colon cancer screening 2Health News:Vendormate and CHCA Finalize Agreement to Offer Compliance and Security Solutions to Children's Hospitals 2Health News:Scientists solve structure of gene regulator that plays key role in cancer 2Health News:Scientists solve structure of gene regulator that plays key role in cancer 3Health News:Quintiles Central Laboratory in India Receives CAP Certification 2Health News:Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc. 2Health News:Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc. 3Health News:Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc. 4
... and 4 metal chest electrodes on ... procedure enabling a patient to easily ... ECG through a simple change of ... per lead and 10 seconds of ...
... IMPACs comprehensive information system designed specifically ... integrate and streamline their diagnostic, management, ... intuitive software solution. Thousands of laboratory ... have proven PowerPaths unique "case-centric model ...
... The Digital-Photo Adapter ... designed optics for the ... technology. In combination with ... this is the best ...
... The CMGS-1 Color Mini-Ganzfeld Stimulator is ... can be integrated with your existing LKC ... with other visual electrodiagnostic test systems. ... is the smallest commercial Ganzfeld to meet ...
Medicine Products: